| Autor: |
Fuhrmann, Stephan, Schabath, Richard, Möricke, Anja, Zimmermann, Martin, Kunz, Joachim B., Kulozik, Andreas E., Ludwig, Wolf‐Dieter, Schrappe, Martin, Karawajew, Leonid, Ratei, Richard |
| Předmět: |
|
| Zdroj: |
British Journal of Haematology; Oct2018, Vol. 183 Issue 1, p96-103, 8p, 2 Charts, 3 Graphs |
| Abstrakt: |
Summary: This study reports the prognostic impact of the expression of the natural killer cell marker CD56 in a large series of risk‐adapted paediatric patients with T cell acute lymphoblastic leukaemia (T‐ALL; n = 493) treated within the ALL‐Berlin‐Frankfurt‐Münster (BFM) 2000 protocol. The immunophenotype was analysed centrally at diagnosis using flow cytometry and correlated with clinical parameters and outcome. CD56 expression was detected in 7·1% and early T‐cell precursor (ETP) phenotype in 6·7% of all T‐ALL patients. The percentage of ETP in the CD56+ T‐ALL cohort was 4‐fold higher than in the whole cohort. CD56+ T‐ALL frequently expressed the progenitor marker CD34 and myeloid antigens CD13 and CD33. The 5‐year event‐free survival (EFS) rates for the European Group for the Immunological classification of Leukaemias/World Health Organization subgroups and the ETP phenotype were not statistically different. By contrast, patients with CD56 expression had a significantly reduced EFS (60 ± 8%) and overall survival (60 ± 8%) at 5 years, with a hazard ratio of 2·46 (P = 0·002) and 2·99 (P < 0·001), respectively. Moreover, CD56 expression in combination with the minimal residual disease (MRD)‐based high risk assignment defined a population with a 'very‐high' risk probability of relapse in the ALL‐BFM 2000 trial. The CD56 marker has the potential to augment MRD‐based risk stratification and may serve as a molecular target for antibody‐based treatment strategies in childhood T‐ALL. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text